Last reviewed · How we verify
Suoquan
Suoquan is a Small molecule drug developed by Children's Hospital of Fudan University. It is currently in Phase 1 development. Also known as: Suoquan mixture.
Suoquan is a Chinese herbal decoction studied for its potential effects on urinary incontinence, specifically stress urinary incontinence and monosymptomatic nocturnal enuresis. It has been investigated in combination with other treatments, such as pelvic floor muscle training and acupuncture, as part of clinical trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Suoquan |
|---|---|
| Also known as | Suoquan mixture |
| Sponsor | Children's Hospital of Fudan University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Chinese Herbal Therapy Combined With Acupuncture for Female Mixed Urinary Incontinence (PHASE2)
- Study on Chinese and Western Medicine in MNE Children (NA)
- A Chinese Herbal Decoction for Stress Urinary Incontinence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suoquan CI brief — competitive landscape report
- Suoquan updates RSS · CI watch RSS
- Children's Hospital of Fudan University portfolio CI
Frequently asked questions about Suoquan
What is Suoquan?
Who makes Suoquan?
Is Suoquan also known as anything else?
What development phase is Suoquan in?
Related
- Manufacturer: Children's Hospital of Fudan University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Suoquan mixture
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing